Adjuvant Therapy with Edrecolomab versus Observation in Stage II Colon Cancer: A Multicenter Randomized Phase III Study*

Publisher： Karger

E-ISSN： 2296-5262|28|6-7|347-350

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.28, Iss.6-7, 2005-06, pp. : 347-350

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

By Punt C.J.   Nagy A.   Douillard J.-Y.   Figer A.   Skovsgaard T.   Monson J.   Barone C.   Fountzilas G.   Riess H.   Moylan E.   Jones D.   Dethling J.   Colman J.   Coward L.   MacGregor S.  

The Lancet, Vol. 360, Iss. 334, 2002-08 ,pp. : 671-677

Elsevier

Access to resources Recommend Favorite

Administration of adjuvant chemotherapy for stage II‐III colon cancer patients: An European population‐based study

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 7, 2018-04 ,pp. : 1480-1489

John Wiley & Sons Inc

Access to resources Recommend Favorite

Usefulness of the Preoperative Administration of Tegafur Suppositories as Alternative Adjuvant Chemotherapy for Patients with Resectable Stage II or III Colorectal Cancer: A KODK4 Multicenter Randomized Control Trial

By  

Oncology, Vol. 83, Iss. 1, 2012-06 ,pp. : 16-23

Karger

Access to resources Recommend Favorite

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 3-4, 2011-03 ,pp. : 204-210

Karger

Access to resources Recommend Favorite

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel (D2) for First-Line Treatment of Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 3-4, 2011-03 ,pp. : 197-203

Karger

Access to resources Recommend Favorite